Endpoints News· Nicole DeFeudis·· 2 天前AI 评分22
ESMO26：Pfizer 肺癌后期失利后另寻方向，BioNTech 与 Bristol Myers 显示早期活性
#ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Bristol Myers show early activity
AI 导读
在 ESMO26 上，Pfizer 在非小细胞肺癌后期研究失利后，转而引用一项针对更早期患者的事后分析，指出这些患者似乎仍有获益。BioNTech 与 Bristol Myers 则在同一会议上展示了早期活性数据。
正文 · 原文
MADRID — Pfizer is moving past its late-stage loss in non-small cell lung cancer, pointing to a post-hoc analysis of earlier-line patients who appear to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源：Endpoints News · endpoints.news